On the molecular level, more than half of pancreatic cancers harbor KRAS, TP53, CDKN2A, and SMAD4/DPC4 mutations, leading to continuous cell proliferation and dysregulated cell cycle control and genomic stability [8]. This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.